Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ Morgan Stanley sees further risk for Qualcomm stock amid memory headwinds (Investing.com) +++ MORGAN STANLEY Aktie -3,49%

MEDPACE Aktie

 >MEDPACE Aktienkurs 
380.5 EUR    -14.7%    (TradegateBSX)
Ask: 379.6 EUR / 30 Stück
Bid: 377.7 EUR / 30 Stück
Tagesumsatz: 64 Stück
Realtime Kurs von 7:30 bis 22 Uhr!
MEDPACE Aktie über LYNX handeln
>MEDPACE Performance
1 Woche: -8,6%
1 Monat: -13,1%
3 Monate: -8,4%
6 Monate: +22,2%
1 Jahr: +33,5%
laufendes Jahr: -6,2%
>MEDPACE Aktie
Name:  MEDPACE HOLDINGS DL-,01
Land:  USA
Sektor:  Gesundheit
ISIN/ Wkn:  US58506Q1094 / A2APTV
Symbol/ Ticker:  01P (Frankfurt) / MEDP (NASDAQ)
Kürzel:  FRA:01P, ETR:01P, 01P:GR, NASDAQ:MEDP
Index:  -
Webseite:  https://www.medpace.com/
Profil:  Medpace Holdings Inc. is a prominent entity in the..
>Volltext..
Marktkapitalisierung:  12904.89 Mio. EUR
Unternehmenswert:  12784.78 Mio. EUR
Umsatz:  1996.15 Mio. EUR
EBITDA:  453.29 Mio. EUR
Nettogewinn:  366.5 Mio. EUR
Gewinn je Aktie:  12.41 EUR
Schulden:  121.86 Mio. EUR
Liquide Mittel:  241.52 Mio. EUR
Operativer Cashflow:  602 Mio. EUR
Bargeldquote:  0.22
Umsatzwachstum:  8.06%
Gewinnwachstum:  12.39%
Dividende je Aktie:  -
Dividendenrendite:  -
Dividendenschätzung:  -
Insiderhandel:  -
Suchwörter:  MEDPACE
Letzte Datenerhebung:  10.02.26
>MEDPACE Kennzahlen
Aktien/ Unternehmen:
Aktien: 28.17 Mio. St.
Frei handelbar: 80.46%
Rückkaufquote: 6.9%
Mitarbeiter: 5900
Umsatz/Mitarb.: 0.3 Mio. EUR
Analysten:
Analystenrating: Neutral
Kursziel: 3.43%
Bewertung:
KGV: 38.41
KGV lG: 37.13
KUV: 7.24
KBV: 52.55
PEG-Ratio: 1.64
EV/EBITDA: 28.2
Rentabilität:
Bruttomarge: 29.9%
Gewinnmarge: 18.36%
Operative Marge: 21.5%
Managementeffizenz:
Gesamtkaprendite: 22.57%
Eigenkaprendite: 73.7%
>MEDPACE Peer Group
Gesundheit, Onkologie/ Krebs- Behandlung
 
10.02.26 - 18:12
Medpace outlines 2026 revenue growth of up to 12.8% amid backlog normalization and metabolic trial shifts (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
10.02.26 - 17:18
Medpace slumps after Q4 earnings on book-to-bill ratio (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
10.02.26 - 16:36
Medpace (MEDP) Q4 2025 Earnings Call Transcript (Fool)
 
Um den gesamten Artikel unter fool.com zu lesen, klicken Sie bitte auf die Überschrift...
10.02.26 - 16:30
Earnings Call Transkript: Medpace übertrifft im Q4 2025 die Erwartungen, Aktie bricht ein/n (Investing.com DE)
 
Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...
10.02.26 - 01:00
Medpace (MEDP) Beats Q4 Earnings and Revenue Estimates (Zacks)
 
Medpace (MEDP) delivered earnings and revenue surprises of +11.79% and +4.01%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?...
09.02.26 - 22:24
Medpace GAAP EPS of $4.67 beats by $0.48, revenue of $708.5M beats by $17.57M (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
09.02.26 - 22:21
Medpace Holdings, Inc. Reports Fourth Quarter and Full Year 2025 Results (Business Wire)
 
Revenue of $708.5 million in the fourth quarter of 2025 increased 32.0% from revenue of $536.6 million for the comparable prior-year period, representing a backlog conversion rate of 23.6%. Net new business awards were $736.6 million in the fourth quarter of 2025, representing an increase of 39.1% from net new business awards of $529.7 million for the comparable prior-year period, which resulted in a net book-to-bill ratio of 1.04x. Fourth quarter of 2025 GAAP net income was $135.1 million, or $4.67 per diluted share, versus GAAP net income of $117.0 million, or $3.67 per diluted share, for the comparable prior-year period. Net income margin was 19.1% and 21.8% for the fourth quarter of 2025 and 2024, respectively. EBITDA was $160.2 million for the fourth quarter of 2025, an increase of 20.0% from EBITDA of $133.5 million for the comparable prior-year period, resulting in an EBITDA margin of 22.6%. CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced financial...
09.02.26 - 14:33
3 Key Trends Transforming the Future of Rare Disease Clinical Development, Upcoming Webinar Hosted by Xtalks (PR Newswire)
 
In this free webinar, learn how to align innovative science with global regulatory expectations to successfully advance rare disease clinical development and programs to drive meaningful change for patients. Join a Medpace rare disease expert as they explore key trends shaping the future......
06.02.26 - 15:33
A Look at Medpace Hldgs′s Upcoming Earnings Report (Benzinga)
 
Importance Rank:  1 read more...
31.01.26 - 01:45
Medpace (MEDP) Declines More Than Market: Some Information for Investors (Zacks)
 
In the most recent trading session, Medpace (MEDP) closed at $582.48, indicating a -1.79% shift from the previous trading day....
24.01.26 - 01:45
Medpace (MEDP) Stock Drops Despite Market Gains: Important Facts to Note (Zacks)
 
In the closing of the recent trading day, Medpace (MEDP) stood at $588.05, denoting a -3.01% move from the preceding trading day....
15.01.26 - 01:45
Why the Market Dipped But Medpace (MEDP) Gained Today (Zacks)
 
Medpace (MEDP) closed at $616.45 in the latest trading session, marking a +1.32% move from the prior day....
12.01.26 - 17:30
Zacks Industry Outlook Highlights Medpace, Enhabit and Progyny (Zacks)
 
Medpace anchors a cautious medical services outlook as digital health tailwinds help select players offset workforce pressures....
09.01.26 - 01:45
Medpace (MEDP) Stock Dips While Market Gains: Key Facts (Zacks)
 
Medpace (MEDP) closed the most recent trading day at $600.02, moving 2.13% from the previous trading session....
05.01.26 - 22:06
Medpace Holdings, Inc. to Report Fourth Quarter and Fiscal Year 2025 Financial Results on February 9, 2026 (Business Wire)
 
CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced that it will report its fourth quarter and fiscal year 2025 financial results after the market close on Monday, February 9, 2026. The Company will host a conference call the following morning, Tuesday, February 10, 2026, at 9:00 a.m. ET to discuss these results. To participate in the conference call, interested parties must register in advance by clicking on this link. While it is not required, it is recommended you join 10 minutes prior to the event start. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique PIN that can be used to access the call. To access the conference call via webcast, visit the “Investors” section of Medpace's website at investor.medpace.com. The webcast replay of the call will be available at the same site approximately one hour after the end of the call. A supp...
01.01.26 - 01:45
Why Medpace (MEDP) Dipped More Than Broader Market Today (Zacks)
 
In the most recent trading session, Medpace (MEDP) closed at $561.65, indicating a -1.27% shift from the previous trading day....
20.12.25 - 01:45
Medpace (MEDP) Outperforms Broader Market: What You Need to Know (Zacks)
 
In the latest trading session, Medpace (MEDP) closed at $568.36, marking a +1.45% move from the previous day....
05.12.25 - 02:01
Insiderhandel: CEO verkauft Aktien von Medpace Holdings im Wert von 394581 USD (Insiderkauf)
 
Troendle, August J. - Vorstand - Tag der Transaktion: 2025-12-03...
04.12.25 - 02:02
Insiderhandel: CEO verkauft Aktien von Medpace Holdings im Wert von 3364498 USD (Insiderkauf)
 
Troendle, August J. - Vorstand - Tag der Transaktion: 2025-12-02...
04.12.25 - 02:02
Insiderhandel: CEO verkauft Aktien von Medpace Holdings im Wert von 13750349 USD (Insiderkauf)
 
Troendle, August J. - Vorstand - Tag der Transaktion: 2025-12-01...
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Das Gegenwärtige ist begrenzt. Das Mögliche ist unermeßlich. - Abraham Lincoln
Partner:    >TradegateBSX Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!